Biopharma and CRO veteran Marshall nabs inflammatory disorder role at Worldwide

Pushpin showing North Carolina on a map
North Carolina-based Worldwide Clinical Trials takes on Philippa Marshall for her immunology experience. (Getty/Creative RF)

Thirty-year life science veteran Philippa Marshall, M.D., has been hired as Worldwide Clinical Trials’ new vice president for scientific solutions in immune-mediated inflammatory disorders.

The North Carolina-based CRO takes on Marshall after a career spanning three decades, with stints at GlaxoSmithKline, Novo Nordisk, inVentiv Health and, more recently, PPD, where her roles focused predominately on immunology, rare diseases and medicines for kids.

“Dr. Marshall brings an unwavering dedication to advancing science and medicine and nearly three decades of therapeutic expertise to our expanding Scientific Solutions team,” said Peter Benton, president and chief operating officer of WCT.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

RELATED: Worldwide Clinical inks partnership deal with Deep Lens

“She will play a key role in providing the innovative insight our customers have come to expect from a CRO of our size. There’s really no substitute for the uncommon combination of world-class therapeutic expertise, global operations and personalized attention our team delivers," Benton added.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.